Estrogen formulations available in the United States
| Ultra-low dose | Low dose | Standard dose | High dose | |
|---|---|---|---|---|
| Oral formulations | ||||
| Conjugated estrogen | Not available (NA) | 0.3, 0.45 mg | 0.625 mg | 0.9, 1.25 mg |
| Esterified estrogen | NA | 0.3 mg | 0.625 mg | 1.25, 2.5 mg |
| Estropipate | NA | NA | 0.75, 1.5 mg | 3 mg |
| Estradiol acetate | NA | 0.45 mg | 0.9 mg | 1.8 mg |
| 17-beta estradiol | 0.25 mg | 0.5 mg | 1, 2 mg | NA |
| Topical formulations | ||||
| Estradiol patch | 0.014 mg/day (14 μg/day) | 0.025 mg/day | 0.0375, 0.05 mg/day | 0.06, 0.075, 0.1 mg/day |
| Gels, pumps, sprays | Various brands of estr adiol available in all dosing options | |||
| Vaginal formulation | ||||
| Femringa | NA | NA | 0.05 mg/day | 1 mg/day |
↵a Femring is the only vaginal formulation in the United States that provides standard/high-dose systemic levels of estrogen. All other vaginal estrogen formulations are indicated to treat only the genitourinary symptoms of menopause through local vaginal effects.